Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Vericel Corporation (VCEL) PT Raised to $60 at TD Cowen
August 26, 2024 12:30 PM EDTTD Cowen analyst Joshua Jennings raised the price target on Vericel Corporation (NASDAQ: VCEL) to $60.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "VCEL announced that the FDA approved its supplemental BLA filing for MACI Arthro. Management had been guiding to a 3Q approval, so we are encouraged to see an FDA decision within the expected timeline. This approval represents an expansion of the current MACI offering to include... More
BTIG Reiterates Buy Rating on Vericel Corporation (VCEL)
August 26, 2024 9:33 AM EDTBTIG analyst Ryan Zimmerman reiterated a Buy rating and $55.00 price target on Vericel Corporation (NASDAQ: VCEL).
The analyst comments "This morning, VCEL announced the FDA approval of the BLA supplement for arthroscopic MACI. The MACI Arthro version provides for the same experience that has made MACI a... More
